The real vancomycin-resistant Staphylococcus aureus has arrived

Clinical Microbiology Newsletter

Volumn 27, Issue 5, 2005, Pages 35-40

  Tenover, Fred C ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL CELL; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; CLINICAL EXAMINATION; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG BINDING SITE; DRUG EFFICACY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; FOLLOW UP; FREQUENCY ANALYSIS; GENETIC RESISTANCE; HUMAN; JAPAN; LACTOBACILLUS; LEUCONOSTOC; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEDIOCOCCUS; PHENOTYPE; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; STANDARD; STAPHYLOCOCCUS AUREUS; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 17144365090     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-4399(05)80005-4     Document Type: Article

References (47)

1. Leclerq R. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium N. Engl. J. Med. 319 1988 157 161
2. Uttley A.H.C. Vancomycin-resistant enterococcus Lancet i 1988 57 58
3. Arthur M. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Entercoccus faecium BM4147 J. Bacteriol. 175 1993 117 127
4. Bugg T.D.H. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA Biochemistry 30 1991 10408 10415
5. Leclercq R., and P. Courvalin Resistance to glycopeptides in enterococci Clin. Infect. Dis. 24 1997 545 556
6. Shlaes D.M. Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256 Antimicrob. Agents Chemother. 33 1989 198 203
7. Centers for Disease Control and Prevention Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin Moth. Mortal. Wkly. Rep. 46 1997 626 635
8. Hospital Infection Control Practices Advisory Committee Recommendations for preventing the spread of vancomycin resistance Infect. Control Hosp. Epidemiol. 16 1995 105 113
9. Wenzel R.P., and M.B. Edmond Vancomycin-resistant Staphylococcus aureus: infection control considerations Clin. Infect. Dis. 27 1998 245 251
10. Nobel W.C., and Z.C.R.G. Virani Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus FEMS Microbiol. Lett. 72 1992 195 198
11. Hiramatsu K. Methicillinresistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J. Antimicrob. Chemother. 40 1997 135 136
12. Cui L. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureusMu50 Antimicrob. Agents Chemother. 44 2000 2276 2285
13. Hanaki H. Activated cellwall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 andMu50 J. Antimicrob. Chemother. 42 1998 199 209
14. Fridkin S.K. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know Clin. Infect. Dis. 32 2001 108 115
15. Sieradzki K. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection N. Engl. J. Med. 340 1999 517 523
16. Smith T.I. Emergence of vancomycin resistance in Staphylococcus aureus N. Engl. J. Med. 340 1999 493 501
17. Oliveira G.A. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin Infect. Control Hosp. Epidemiol. 22 2001 443 448
18. Ploy M.C. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital Lancet 351 1998 1212
19. Kim M.N. Vancomycinintermediate Staphylococcus aureus in Korea J. Clin. Microbiol. 38 2000 3879 3891
20. Tenover F.C. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides J. Clin. Microbiol. 36 1998 1020 1027
21. Hussain F.M. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates J. Infect. Dis. 186 2002 661 667
22. Pfeltz R.F. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds Antimicrob. Agents Chemother. 44 2000 294 303
23. Fridkin S.K. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin,United States, 1997-2001 Clin. Infect. Dis. 36 2003 429 439
24. Chang S. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene N. Engl. J. Med. 348 2003 1342 1347
25. Weigel L.M. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus Science 302 2003 1569 1571
26. Severin A. High level oxacillin and vancomycin resistance and altered cell wall composition in Staphylococcus aureus carrying the staphylococcal mecA and enterococcal vanA gene complex J. Biol. Chem. 279 2004 3398 3407
27. Centers for Disease Control and Prevention Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002 Morb. Mortal. Wkly. Rep. 51 2002 902
28. Whitener C.J. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure Clin. Infect. Dis. 38 2004 1049 1055
29. Bozdogan B. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center J. Antimicrob. Chemother. 52 2003 864 868
30. Tenover F.C. Characterization of a vancomycin-resistant clinical isolate of Staphylococcus aureus from Pennsylvania Antimicrob. Agents Chemother. 48 2004 275 280
31. Clark N.A. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus (VRSA) isolates from Michigan and Pennsylvania Antimicrob. Agents Chemother. 49 2005 470 472
32. McDougal L.K. Pulsed-field gel electrophoresis typing of oxacillinresistant Staphylococcus aureus isolates from the United States: establishing a national database J. Clin Microbiol. 41 2003 5113 5120
33. Aires-de-Sousa M. Similarity of antibiotic resistance patterns and molecular typing properties of methicillin-resistant Staphylococcus aureus (MRSA) isolateswidely spread in New York City and in a hospital in Tokyo, Japan Microb. Drug Resist. 6 2000 253 258
34. Centers for Disease Control and Prevention Vancomycin-resistant Staphylococcus aureus-New York, 2004 Morb. Mortal. Wkly. Rep. 53 2004 322 323
35. Carey R. Failure of automated systems to detect vancomycinresistant Staphylococcus aureus, abstr. D-66 Abstracts 44th Int. Conf. Antimicrob. Agents Chemother. 2004 2004 American Society for Microbiology Washington, D.C.
36. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance Lancet Infect. Dis. 1 2002 147 155
37. Hiramatsu K. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin Lancet 350 1997 1670 1673
38. Wootton M. A modified population analysis profile (PAP) method to detect heteroresistance to vancomycin in Staphylococcus aureus in a UK hospital J. Antimicrob. Agents Chemother. 47 2001 399 403
39. Ariza J. Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin Lancet 353 1999 1587 1588
40. Van Griethuysen A. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in the Netherlands J. Clin. Microbiol. 41 2003 2487 2491
41. Goldstein F.W., and M.D. Kitzis Vancomycin-resistant Staphylococcus aureus: no apocalypse now Clin. Microbiol. Infect. 9 2003 761 765
42. Approved standard NCCLS Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically M7-A6 6th ed. 2003 National Committee for Clinical Laboratory Standards Washington, D.C.
43. Walsh T.R. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides J. Clin. Microbiol. 39 2001 2439 2444
44. Charles P.G.P. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus Clin. Infect. Dis. 38 2004 448 451
45. Sakoulas G. Relationship of MIC bactericidal activity to efficacy of vancomycin treatment of methicillin-resistant Staphylococcus aureus bacteremia J. Clin. Microbiol. 42 2004 2398 2402
46. Moore M.R., E. Remington-Perdreau, and H.F. Chambers Vancomycin treatment failure associated with heterogeneous vancomycin intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis Antimicrob. Agents Chemother. 47 2003 1262 1266
47. Cunha B.A. Vancomycin Med. Clin. N. Am. 79 1995 817 831